Optimizing Treatment for HR+/HER2- Breast Cancer: A Multidisciplinary Approach

A panel of experts explains the importance of a multidisciplinary team in treating HR+/HER2- breast cancer to ensure comprehensive and coordinated care throughout the patient's journey.

Key opinion leaders detail various barriers to optimal care for patients with HR+/HER2- breast cancer, including transportation issues, financial difficulties, lack of family support, and challenges in coordinating care among different medical specialists.

Naomi Dempsey, MD, presents the clinical scenario of a 60-year-old woman with newly diagnosed HR+/HER- breast cancer to the panel for discussion.

The panel discusses the importance of careful chemotherapy dosing and management of side effects for patients with HR+/HER- breast cancer, including the use of cooling and compression gloves to prevent peripheral neuropathy.

Experts explain the challenges patients with HR+/HER- breast cancer face in accessing abemaciclib for treatment and the options available such as patient assistance programs for high co-pays.

Dr Naomi Dempsey shares the study design, primary outcome data, and the 3-year invasive disease-free survival follow-up data from the NATALEE trial in HR+/HER2- breast cancer presented at ASCO 2023.

Nadia Nocera Zachariah, MD, explains why early detection and monitoring of lymphedema is crucial in patients with HR+/HER- breast cancer, with technologies like prophylactic compression sleeves and nighttime compression systems showing promise in reducing negative impact on quality of life.

Naomi Dempsey, MD, reviews data on the use of CDK4/6 inhibitors for the frontline treatment of metastatic HR+/HER- breast cancer.

Dr Naomi Dempsey explains how she decides on an appropriate CDK4/6 inhibitor for patients receiving first-line treatment for metastatic HR+/HER- breast cancer.

The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.

Experts debate the utility of surgery on the primary tumor in patients with novel metastatic HR+/HER- breast cancer.

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.